3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Radiosurgery
22
Ipilimumab
17
Nivolumab
16
pembrolizumab
11
Temozolomide
9
encorafenib
8
dabrafenib
8
binimetinib
8
Magnetic Resonance Spectroscopy
6
trametinib
5
Bevacizumab
5
CTLA-4 Antigen
4
cobimetinib
3
Thalidomide
3
Radiotherapy
3
Paclitaxel
3
entrectinib
2
cediranib
2
Vemurafenib
2
Spermine Synthase
2
Specimen Handling
2
Radiation
2
Pemetrexed
2
Opdualag
2
Drug Therapy
2
Carboplatin
2
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
2
14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione
2
130-nm albumin-bound paclitaxel
2
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
Patient-Specific Modeling
×
Dermatologic
×
Clear all
NCT02000739
2014-07-14
GENIUS
Dartmouth-Hitchcock Medical Center
Phase 4
Withdrawn